Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches
Amgen and Allergan launched the first US biosimilar for Roche's Herceptin – and the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Infographic reviews Herceptin's past and its future competitors.
You may also be interested in...
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.
Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.